{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:52:57Z","timestamp":1792093977303,"version":"4.4.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM140862"],"award-info":[{"award-number":["R35GM140862"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL147028"],"award-info":[{"award-number":["R01HL147028"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40259-024-00665-2","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T23:52:21Z","timestamp":1719273141000},"page":"511-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs"],"prefix":"10.1007","volume":"38","author":[{"given":"Angela","family":"Sang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adara","family":"Bochanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Bahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9450-3394","authenticated-orcid":false,"given":"Theodore P.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"5\u20136","key":"665_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006;33(5\u20136):533\u201340. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04403.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"665_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168875","author":"V Barresi","year":"2022","unstructured":"Barresi V, Musmeci C, Rinaldi A, Condorelli DF. Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23168875.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"665_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1515\/mr-2023-0062","volume":"4","author":"M Teng","year":"2021","unstructured":"Teng M, Xia ZJ, Lo N, Daud K. He HH (2024) Assembling the RNA therapeutics toolbox. Med Rev. 2021;4(2):110\u201328. https:\/\/doi.org\/10.1515\/mr-2023-0062.","journal-title":"Med Rev"},{"key":"665_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.04.021","author":"BP Vinjamuri","year":"2024","unstructured":"Vinjamuri BP, Pan J, Peng P. A review on commercial oligonucleotide drug products. J Pharm Sci. 2024. https:\/\/doi.org\/10.1016\/j.xphs.2024.04.021.","journal-title":"J Pharm Sci"},{"key":"665_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259\u201393. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"665_CR6","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1016\/j.celrep.2019.10.108","volume":"29","author":"A Lockhart","year":"2019","unstructured":"Lockhart A, Pires VB, Bento F, Kellner V, Luke-Glaser S, Yakoub G, Ulrich HD, Luke B. RNase H1 and H2 are differentially regulated to process RNA-DNA hybrids. Cell Rep. 2019;29(9):2890-2900e2895. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.108.","journal-title":"Cell Rep"},{"key":"665_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.102672","volume":"84","author":"M Hyjek","year":"2019","unstructured":"Hyjek M, Figiel M, Nowotny M. RNases H: structure and mechanism. DNA Repair (Amst). 2019;84: 102672. https:\/\/doi.org\/10.1016\/j.dnarep.2019.102672.","journal-title":"DNA Repair (Amst)"},{"key":"665_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1146\/annurev.biochem.73.012803.092453","volume":"73","author":"Y Liu","year":"2004","unstructured":"Liu Y, Kao HI, Bambara RA. Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem. 2004;73:589\u2013615. https:\/\/doi.org\/10.1146\/annurev.biochem.73.012803.092453.","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"665_CR9","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017;25(9):2075\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.002.","journal-title":"Mol Ther"},{"issue":"3","key":"665_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s12276-020-0407-z","volume":"52","author":"SH Boo","year":"2020","unstructured":"Boo SH, Kim YK. The emerging role of RNA modifications in the regulation of mRNA stability. Exp Mol Med. 2020;52(3):400\u20138. https:\/\/doi.org\/10.1038\/s12276-020-0407-z.","journal-title":"Exp Mol Med"},{"issue":"3","key":"665_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek K, Das R, Barna M. Functional 5\u2019 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19(3):158\u201374. https:\/\/doi.org\/10.1038\/nrm.2017.103.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"665_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/gtc.12587","volume":"23","author":"T Yoshida","year":"2018","unstructured":"Yoshida T, Naito Y, Sasaki K, Uchida E, Sato Y, Naito M, Kawanishi T, Obika S, Inoue T. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences. Genes Cells. 2018;23(6):448\u201355. https:\/\/doi.org\/10.1111\/gtc.12587.","journal-title":"Genes Cells"},{"issue":"11","key":"665_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/bioinformatics\/17.11.1058","volume":"17","author":"RK Far","year":"2001","unstructured":"Far RK, Nedbal W, Sczakiel G. Concepts to automate the theoretical design of effective antisense oligonucleotides. Bioinformatics. 2001;17(11):1058\u201361. https:\/\/doi.org\/10.1093\/bioinformatics\/17.11.1058.","journal-title":"Bioinformatics"},{"issue":"10","key":"665_CR14","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/nar\/29.10.2041","volume":"29","author":"M Sohail","year":"2001","unstructured":"Sohail M, Hochegger H, Klotzbucher A, Guellec RL, Hunt T, Southern EM. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res. 2001;29(10):2041\u201351. https:\/\/doi.org\/10.1093\/nar\/29.10.2041.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"665_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2008.205","volume":"17","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, de Kimpe S, van Deutekom JC, t Hoen PA, van Ommen GJ. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther. 2009;17(3):548\u201353. https:\/\/doi.org\/10.1038\/mt.2008.205.","journal-title":"Mol Ther"},{"issue":"15","key":"665_CR16","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/nar\/28.15.2862","volume":"28","author":"OV Matveeva","year":"2000","unstructured":"Matveeva OV, Tsodikov AD, Giddings M, Freier SM, Wyatt JR, Spiridonov AN, Shabalina SA, Gesteland RF, Atkins JF. Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res. 2000;28(15):2862\u20135. https:\/\/doi.org\/10.1093\/nar\/28.15.2862.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"665_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","volume":"21","author":"A Verma","year":"2018","unstructured":"Verma A. Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases. Ann Indian Acad Neurol. 2018;21(1):3\u20138. https:\/\/doi.org\/10.4103\/aian.AIAN_298_17.","journal-title":"Ann Indian Acad Neurol"},{"issue":"6","key":"665_CR18","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1093\/nar\/gkh516","volume":"32","author":"BH Yoo","year":"2004","unstructured":"Yoo BH, Bochkareva E, Bochkarev A, Mou TC, Gray DM. 2\u2019-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 2004;32(6):2008\u201316. https:\/\/doi.org\/10.1093\/nar\/gkh516.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"665_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","volume":"12","author":"MA Gertz","year":"2019","unstructured":"Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol. 2019;12(8):701\u201311. https:\/\/doi.org\/10.1080\/17512433.2019.1635008.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"665_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00415-019-09671-9","volume":"267","author":"T Coelho","year":"2020","unstructured":"Coelho T, Yarlas A, Waddington-Cruz M, White MK, Sikora Kessler A, Lovley A, Pollock M, Guthrie S, Ackermann EJ, Hughes SG, Karam C, Khella S, Gertz M, Merlini G, Obici L, Schmidt HH, Polydefkis M, Dyck PJB, Brannagan Iii TH, Conceicao I, Benson MD, Berk JL. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol. 2020;267(4):1070\u20139. https:\/\/doi.org\/10.1007\/s00415-019-09671-9.","journal-title":"J Neurol"},{"key":"665_CR21","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther. 2019;13:1515\u201325. https:\/\/doi.org\/10.2147\/DDDT.S162913.","journal-title":"Drug Des Devel Ther"},{"key":"665_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020078","author":"L Gales","year":"2019","unstructured":"Gales L. Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel). 2019. https:\/\/doi.org\/10.3390\/ph12020078.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"665_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793.","journal-title":"N Engl J Med"},{"issue":"15","key":"665_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Franca MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceicao I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M, Investigators NE-T. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358. https:\/\/doi.org\/10.1001\/jama.2023.18688.","journal-title":"JAMA"},{"issue":"1","key":"665_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021;8(1):652\u201361. https:\/\/doi.org\/10.1002\/ehf2.13154.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"665_CR26","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.4049\/jimmunol.168.7.3464","volume":"168","author":"B Park","year":"2002","unstructured":"Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, Hwang SY, Ahn K. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J Immunol. 2002;168(7):3464\u20139. https:\/\/doi.org\/10.4049\/jimmunol.168.7.3464.","journal-title":"J Immunol"},{"issue":"2","key":"665_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/eye.2011.327","volume":"26","author":"A Carmichael","year":"2012","unstructured":"Carmichael A. Cytomegalovirus and the eye. Eye (Lond). 2012;26(2):237\u201340. https:\/\/doi.org\/10.1038\/eye.2011.327.","journal-title":"Eye (Lond)"},{"issue":"2","key":"665_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ajo.2010.10.018","volume":"151","author":"DA Jabs","year":"2011","unstructured":"Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome\u2013bench to bedside: LXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011;151(2):198-216e191. https:\/\/doi.org\/10.1016\/j.ajo.2010.10.018.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"665_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/infdis\/166.6.1223","volume":"166","author":"JE Gallant","year":"1992","unstructured":"Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166(6):1223\u20137. https:\/\/doi.org\/10.1093\/infdis\/166.6.1223.","journal-title":"J Infect Dis"},{"key":"665_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/v12010110","author":"CS Adamson","year":"2020","unstructured":"Adamson CS, Nevels MM. Bright and early: inhibiting human cytomegalovirus by targeting major immediate-early gene expression or protein function. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12010110.","journal-title":"Viruses"},{"issue":"3","key":"665_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/v1030760","volume":"1","author":"C Paulus","year":"2009","unstructured":"Paulus C, Nevels M. The human cytomegalovirus major immediate-early proteins as antagonists of intrinsic and innate antiviral host responses. Viruses. 2009;1(3):760\u201379. https:\/\/doi.org\/10.3390\/v1030760.","journal-title":"Viruses"},{"issue":"9","key":"665_CR32","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1128\/AAC.40.9.2004","volume":"40","author":"KP Anderson","year":"1996","unstructured":"Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother. 1996;40(9):2004\u201311. https:\/\/doi.org\/10.1128\/AAC.40.9.2004.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"665_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccl.2015.01.001","volume":"33","author":"VE Bouhairie","year":"2015","unstructured":"Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin. 2015;33(2):169\u201379. https:\/\/doi.org\/10.1016\/j.ccl.2015.01.001.","journal-title":"Cardiol Clin"},{"key":"665_CR34","unstructured":"Feingold KR. Cholesterol lowering drugs. In: Feingold KR, Anawalt B, Boyce A et al. (eds). 2000; Endotext. South Dartmouth (MA)"},{"key":"665_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd8070082","author":"B Astaneh","year":"2021","unstructured":"Astaneh B, Makhdami N, Astaneh V, Guyatt G. The effect of mipomersen in the management of patients with familial hypercholesterolemia: a systematic review and meta-analysis of clinical trials. J Cardiovasc Dev Dis. 2021. https:\/\/doi.org\/10.3390\/jcdd8070082.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"665_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","volume":"20","author":"JS Parham","year":"2019","unstructured":"Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother. 2019;20(2):127\u201331. https:\/\/doi.org\/10.1080\/14656566.2018.1550071.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"665_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","volume":"79","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs. 2019;79(7):751\u201366. https:\/\/doi.org\/10.1007\/s40265-019-01114-z.","journal-title":"Drugs"},{"issue":"5","key":"665_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1073858414561795","volume":"21","author":"RK Bunton-Stasyshyn","year":"2015","unstructured":"Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21(5):519\u201329. https:\/\/doi.org\/10.1177\/1073858414561795.","journal-title":"Neuroscientist"},{"issue":"8","key":"665_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/jnnp-2017-317611","volume":"89","author":"K Muller","year":"2018","unstructured":"Muller K, Brenner D, Weydt P, Meyer T, Grehl T, Petri S, Grosskreutz J, Schuster J, Volk AE, Borck G, Kubisch C, Klopstock T, Zeller D, Jablonka S, Sendtner M, Klebe S, Knehr A, Gunther K, Weis J, Claeys KG, Schrank B, Sperfeld AD, Hubers A, Otto M, Dorst J, Meitinger T, Strom TM, Andersen PM, Ludolph AC, Weishaupt JH, German ALSnMNDNET. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89(8):817\u201327. https:\/\/doi.org\/10.1136\/jnnp-2017-317611.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"665_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.27818","volume":"67","author":"T Meyer","year":"2023","unstructured":"Meyer T, Schumann P, Weydt P, Petri S, Koc Y, Spittel S, Bernsen S, Gunther R, Weishaupt JH, Dreger M, Kolzarek F, Kettemann D, Norden J, Boentert M, Vidovic M, Meisel C, Munch C, Maier A, Kortvelyessy P. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice. Muscle Nerve. 2023;67(6):515\u201321. https:\/\/doi.org\/10.1002\/mus.27818.","journal-title":"Muscle Nerve"},{"issue":"8","key":"665_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759\u201364. https:\/\/doi.org\/10.1111\/jpc.12868.","journal-title":"J Paediatr Child Health"},{"issue":"10","key":"665_CR42","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168\u201384. https:\/\/doi.org\/10.3390\/molecules201018168.","journal-title":"Molecules"},{"key":"665_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533\u201345. https:\/\/doi.org\/10.2147\/DDDT.S97635.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"665_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","volume":"59","author":"A Anna","year":"2018","unstructured":"Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59(3):253\u201368. https:\/\/doi.org\/10.1007\/s13353-018-0444-7.","journal-title":"J Appl Genet"},{"issue":"10","key":"665_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.nmd.2021.08.004","volume":"31","author":"F Fortunato","year":"2021","unstructured":"Fortunato F, Farne M, Ferlini A. The DMD gene and therapeutic approaches to restore dystrophin. Neuromuscul Disord. 2021;31(10):1013\u201320. https:\/\/doi.org\/10.1016\/j.nmd.2021.08.004.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"665_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12881-016-0318-y","volume":"17","author":"M Meregalli","year":"2016","unstructured":"Meregalli M, Maciotta S, Angeloni V, Torrente Y. Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26. BMC Med Genet. 2016;17(1):55. https:\/\/doi.org\/10.1186\/s12881-016-0318-y.","journal-title":"BMC Med Genet"},{"issue":"12","key":"665_CR47","first-page":"2675","volume":"6","author":"MA Lewandowska","year":"2013","unstructured":"Lewandowska MA. The missing puzzle piece: splicing mutations. Int J Clin Exp Pathol. 2013;6(12):2675\u201382.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"665_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","volume":"4","author":"M Matsuo","year":"2021","unstructured":"Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy. JMA J. 2021;4(3):232\u201340. https:\/\/doi.org\/10.31662\/jmaj.2021-0019.","journal-title":"JMA J"},{"issue":"10","key":"665_CR49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi RR, Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc). 2019;55(10):627\u201339. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045038.","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"665_CR50","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","volume":"15","author":"PB Shieh","year":"2018","unstructured":"Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15(4):840\u20138. https:\/\/doi.org\/10.1007\/s13311-018-00687-z.","journal-title":"Neurotherapeutics"},{"key":"665_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107719","volume":"220","author":"M Iftikhar","year":"2021","unstructured":"Iftikhar M, Frey J, Shohan MJ, Malek S, Mousa SA. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther. 2021;220: 107719. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107719.","journal-title":"Pharmacol Ther"},{"key":"665_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/CPAA.S288842","volume":"13","author":"RR Roshmi","year":"2021","unstructured":"Roshmi RR, Yokota T. Pharmacological profile of viltolarsen for the treatment of Duchenne muscular dystrophy: a Japanese experience. Clin Pharmacol. 2021;13:235\u201342. https:\/\/doi.org\/10.2147\/CPAA.S288842.","journal-title":"Clin Pharmacol"},{"key":"665_CR53","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","volume":"9","author":"Y Nan","year":"2018","unstructured":"Nan Y, Zhang YJ. Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds. Front Microbiol. 2018;9:750. https:\/\/doi.org\/10.3389\/fmicb.2018.00750.","journal-title":"Front Microbiol"},{"issue":"1","key":"665_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/adna.2.1.15425","volume":"2","author":"C Brolin","year":"2011","unstructured":"Brolin C, Shiraishi T. Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD). Artif DNA PNA XNA. 2011;2(1):6\u201315. https:\/\/doi.org\/10.4161\/adna.2.1.15425.","journal-title":"Artif DNA PNA XNA"},{"issue":"R2","key":"665_CR55","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","volume":"27","author":"L Echevarria","year":"2018","unstructured":"Echevarria L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163\u201372. https:\/\/doi.org\/10.1093\/hmg\/ddy171.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"665_CR56","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY. Eteplirsen: first global approval. Drugs. 2016;76(17):1699\u2013704. https:\/\/doi.org\/10.1007\/s40265-016-0657-1.","journal-title":"Drugs"},{"issue":"1","key":"665_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Krieg AM. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 2017;27(1):1\u20133. https:\/\/doi.org\/10.1089\/nat.2016.0657.","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"665_CR58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo YA. Golodirsen: first approval. Drugs. 2020;80(3):329\u201333. https:\/\/doi.org\/10.1007\/s40265-020-01267-2.","journal-title":"Drugs"},{"key":"665_CR59","unstructured":"Golodirsen. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012; Bethesda (MD)"},{"issue":"8","key":"665_CR60","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T. Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc). 2020;56(8):491\u2013504. https:\/\/doi.org\/10.1358\/dot.2020.56.8.3159186.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"665_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","volume":"30","author":"A Aartsma-Rus","year":"2020","unstructured":"Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30(2):67\u201370. https:\/\/doi.org\/10.1089\/nat.2020.0845.","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"665_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F, Group S-NS. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther. 2022;32(1):29\u201339. https:\/\/doi.org\/10.1089\/nat.2021.0043.","journal-title":"Nucleic Acid Ther"},{"issue":"9","key":"665_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","volume":"27","author":"K Dzierlega","year":"2020","unstructured":"Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. 2020;27(9):407\u201316. https:\/\/doi.org\/10.1038\/s41434-020-0156-6.","journal-title":"Gene Ther"},{"issue":"10","key":"665_CR64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14737175.2023.2246658","volume":"23","author":"E Czifrus","year":"2023","unstructured":"Czifrus E, Berlau DJ. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy. Expert Rev Neurother. 2023;23(10):853\u20138. https:\/\/doi.org\/10.1080\/14737175.2023.2246658.","journal-title":"Expert Rev Neurother"},{"key":"665_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713","author":"H Komaki","year":"2018","unstructured":"Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Sasaki M, Tachimori H, Nakamura H, Aoki Y, Takeda S. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aan0713.","journal-title":"Sci Transl Med"},{"issue":"12","key":"665_CR66","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Takeshita E, Iwata Y, Yajima H, Egawa Y, Toramoto T, Tajima M, Takeda S. Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study. Ann Clin Transl Neurol. 2020;7(12):2393\u2013408. https:\/\/doi.org\/10.1002\/acn3.51235.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"665_CR67","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M. Casimersen: first approval. Drugs. 2021;81(7):875\u20139. https:\/\/doi.org\/10.1007\/s40265-021-01512-2.","journal-title":"Drugs"},{"issue":"1","key":"665_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","volume":"61","author":"T Gidaro","year":"2019","unstructured":"Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019;61(1):19\u201324. https:\/\/doi.org\/10.1111\/dmcn.14027.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"665_CR69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24(3):194\u2013203. https:\/\/doi.org\/10.5863\/1551-6776-24.3.194.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"665_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1060028018789956","volume":"53","author":"MK Claborn","year":"2019","unstructured":"Claborn MK, Stevens DL, Walker CK, Gildon BL. Nusinersen: a treatment for spinal muscular atrophy. Ann Pharmacother. 2019;53(1):61\u20139. https:\/\/doi.org\/10.1177\/1060028018789956.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"665_CR71","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, Muller-Felber W, Shieh PB, Richardson R, Natarajan N, Castro D, Ramirez-Schrempp D, Gambino G, Sun P, Farwell W. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle Nerve. 2021;63(5):668\u201377. https:\/\/doi.org\/10.1002\/mus.27187.","journal-title":"Muscle Nerve"},{"issue":"17","key":"665_CR72","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, Pendergast MK, Goldkind SF, Lee EA, Kuniholm A, Soucy A, Vaze J, Belur NR, Fredriksen K, Stojkovska I, Tsytsykova A, Armant M, DiDonato RL, Choi J, Cornelissen L, Pereira LM, Augustine EF, Genetti CA, Dies K, Barton B, Williams L, Goodlett BD, Riley BL, Pasternak A, Berry ER, Pflock KA, Chu S, Reed C, Tyndall K, Agrawal PB, Beggs AH, Grant PE, Urion DK, Snyder RO, Waisbren SE, Poduri A, Park PJ, Patterson A, Biffi A, Mazzulli JR, Bodamer O, Berde CB, Yu TW. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381(17):1644\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1813279.","journal-title":"N Engl J Med"},{"issue":"3","key":"665_CR73","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jnr.25147","volume":"101","author":"G Nittari","year":"2023","unstructured":"Nittari G, Tomassoni D, Roy P, Martinelli I, Tayebati SK, Amenta F. Batten disease through different in vivo and in vitro models: a review. J Neurosci Res. 2023;101(3):298\u2013315. https:\/\/doi.org\/10.1002\/jnr.25147.","journal-title":"J Neurosci Res"},{"key":"665_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/DNND.S111967","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73\u201383. https:\/\/doi.org\/10.2147\/DNND.S111967.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"14","key":"665_CR75","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44(14):6549\u201363. https:\/\/doi.org\/10.1093\/nar\/gkw533.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"665_CR76","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(4):914-921e910. https:\/\/doi.org\/10.1016\/j.cell.2020.04.011.","journal-title":"Cell"},{"issue":"2","key":"665_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281281","volume":"18","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Wotring JW, Zhang CJ, Jiang X, Xiao L, Watt A, Gattis D, Scandalis E, Freier S, Zheng Y, Pretto CD, Ellison SJ, Swayze EE, Guo S, Sexton JZ, Chinnaiyan AM. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PLoS ONE. 2023;18(2): e0281281. https:\/\/doi.org\/10.1371\/journal.pone.0281281.","journal-title":"PLoS ONE"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00665-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T22:17:57Z","timestamp":1720995477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00665-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00665-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the US National Institutes of Health (NIH) National Institute of General Medical Sciences [Grant R35GM140862 to X.B.Z.], National Heart, Lung, and Blood Institute [R01HL147028 to R.B.], an Endowment Fund from Boehringer Ingelheim Pharmaceuticals, Inc. [JEM], and internal funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No author has an actual or perceived conflict of interest with the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.S., S.Z., and A.B. conceptualized the study and performed data curation and writing\u2014original draft preparation; J.E.M., R.B., X.Z., and T.P.R. carried out writing\u2014reviewing and editing. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}